Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis

The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.

Inclusion Criteria:

• Diagnosis of RA
• Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA
• Active RA at time of screening and baseline

Exclusion Criteria:

• Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents
• Concurrent treatment with a DMARD, other than MTX, at screening
• Receipt of any DMARD, other than MTX, within 3 months before screening